Full coveragePhysician Views Preview: As Gilead 'PrEPs' for new era with Yeztugo, the focus turns to prescribers
By Jessica D'Amico
Posts on X
Formerly Twitter
Gilead Sciences
GileadSciences
At Gilead, we're focused on delivering transformative therapies in #HIV and pushing the boundaries of scientific innovation in our mission to help end the epidemic. Here's what it takes. pic.x.com/r0rDCSjpjS
Posted on X
UNAIDS Global
UNAIDS
#PCB56 has started.
Ambassador Cecilia Kiku Ishitani, Chair of PCB, highlights the crisis in the global HIV response and applauds Member States and partners for stepping up. She calls for breakthrough prevention #Lenacapavir to be accessible and affordable.
@DelBrasGen pic.x.com/V7LUX6acLq
Posted on X
Unitaid
UNITAID
Medical innovation must serve global equity. Lenacapavir holds promise, but we need governments, funders, and industry to ensure it reaches everyone in need.
Thank you @PBS @NewsHour and @LauraSanthanam for bringing attention to this.
Learn more: www.pbs.org/newshour/health/6-things-to-know-about-lenacapavir-what-experts-call-a-wonder-drug-for-preventing-hiv pic.x.com/Un34m3RDcW
Posted on X
Unitaid
UNITAID
Unitaid is working with partners to make generic lenacapavir available quickly and affordably. Approvals mean little without access. Thanks @evolambert for an in-depth look at what’s needed next in @NPR’s excellent coverage.
Learn more: www.npr.org/sections/goats-and-soda/2025/06/18/g-s1-73130/hiv-prevention-drug-lenacapavir-fda-breakthrough
Posted on X
All coverage
HIV Prevention Has a Fantastic New Treatment
By Richard Seifman
FDA approves HIV medication Lenacapavir, but it's costly
By Jonathan Lambert
Breakthrough in HIV prevention LENACAPAVIR OFFERS NEW HOPE
By Ivninder Pal Singh
Cost Will Be Massive Barrier in Access to Lenacapavir After Approval in the US: Gordon Crofoot, MD, PA
By Julia Bonavitacola
FDA approves new HIV prevention drug
By Candice Bruce
With Lenacapavir 'You've Basically Got a Vaccine.' But Reaching the People Who Would Benefit Is Difficult, Says Gates Foundation Expert
By Logan Lutton and Peter Wehrwein
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
By Josh Nathan-kazis
Here’s what everyone should know about this new HIV prevention shot
By Teddy Amenabar and Richard Sima
Will Big Pharma Greed Consume Promise of 'HIV-Ending' Shot?
By Jessica Corbett
Another tool in the fight against HIV — and more
By Patrick Elwood
Successful clinical trials for two injection a year for HIV treatment, with no side effects
By Sudeshna Panda
Twice-a-year HIV prevention shot Yeztugo could be a game changer for Jackson and beyond
By Bethal Miles
As US FDA approves HIV prevention drug Lenacapavir, expert says ‘India needs to take lead for its equitable, timely distribution
By Anuradha Mascarenhas
New HIV Prevention Drug Approved—Now Let’s Remove the Final Barrier
By Jeffrey A. Singer
HIV prevention drug hailed as a 'breakthrough' gets FDA approval : Goats and Soda
By Jonathan Lambert
Powerful twice-a-year HIV drug that could stop transmission approved
By Lauran Neergaard
FDA approves new twice-yearly HIV shot. What to know
By Ken Alltucker
US FDA approves Gilead's twice-yearly injection for HIV prevention
By Deena Beasley and Julie Steenhuysen
HIV protection with just two shots a year: FDA approves Gilead drug
By Ed Silverman and Jason Mast
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
By Annika Kim Constantino
FDA approves twice-a-year injection for HIV prevention
By Jacqueline Howard